Further understanding of upstream PRMT5 regulators and downstream PRMT5 targets in activated Th cells should provide novel and useful therapeutic targets in the treatment of T cell-mediated autoimmune diseases such as MS. This evidence concerns the gene PRMT5 and autoimmune disease.